香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 1 當日，中國同輻正式啟動穩定同位素基地二期項目建設，項目建成後，中國同輻 將形成高豐度13CO氣體、碳13尿素原料藥以及其它覆蓋胃腸道疾病治療藥物原 料藥的穩定供應能力，對提升國民健康水平、促進醫用同位素高質量發展、服務 「健康中國」建設具有重要意義。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年10月31日 自願性公告 中國同輻突破呼氣診斷關鍵原料技術 成為完整掌握呼氣試驗產品全產業鏈的龍頭企業 本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 本公司董事會（「董事會」）欣然宣佈，10月31日，中國同輻發佈碳同位素產品，標 誌着我國在穩定同位素領 ...

Core Viewpoint - The company, 原子高科, has been recognized as a national-level "specialized, refined, and innovative" small giant enterprise, highlighting its innovation and expertise in nuclear technology applications [1] Group 1: Recognition and Standards - 原子高科 has been included in the national-level list of specialized and innovative small giant enterprises, which is a recognition of its capabilities in the field of radioactive isotope technology [1] - The evaluation criteria for this recognition include business focus, R&D investment intensity, innovation capability, and market share, indicating that 原子高科 excels in these core dimensions [1] Group 2: Implications and Future Directions - This recognition marks 原子高科's entry into the national key cultivation tier, providing an opportunity for the company to enhance its core competitiveness [1] - The company aims to uphold and promote the spirit of craftsmanship, focusing on technological innovation driven by market demand to contribute more to human health [1]

Core Viewpoint - China Tongfu (01763) announced that Atomic High-Tech Co., Ltd. has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, highlighting its innovation and expertise in nuclear technology applications [1] Group 1 - The selection criteria for the national-level "small giant" enterprises include focus on main business, intensity of R&D investment, innovation capability, and market share [1] - Atomic High-Tech is acknowledged as a leader in the niche market of radioactive isotope technology, achieving a domestic leading level in specialization, refinement, distinctiveness, and innovation capability [1] - This recognition marks Atomic High-Tech's entry into the national key cultivation tier, providing an opportunity to enhance its core competitiveness through craftsmanship, technological innovation, and market demand orientation [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 於其他海外監管市場發佈的公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條的規定而發出。 以下公告的中文原稿由中國同輻股份有限公司旗下一間於全國中小企業股份轉讓 系統上市的附屬公司，原子高科股份有限公司（股份代號：430005）於中國境內發 佈。 茲載列原子高科股份有限公司於2025年10月29日於全國中小企業股份轉讓系統 網站(www.neeq.com.cn)刊登的「原子高科股份有限公司關於榮獲國家級專精特新 「小巨人」稱號的公告」，僅供參考。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年10月29日 於本公告日期，董事會成員包括執行董事肖亞飛先生、張軍旗先生、霍穎穎女士 及馬曉宇女士；非執行 ...

Core Viewpoint - China Tongru (01763) has been recognized for its ESG practices at the ESG China Innovation Annual Conference (2025), highlighting its commitment to health and sustainable development through nuclear technology [1] Group 1: ESG Recognition - The company received the "China ESG Excellence Practice (2025)" award from the China Enterprise Reform and Development Research Association [1] - It was also listed among the "China ESG Listed Central Enterprises Pioneer 100 (2025)" by the China Central Radio and Television [1] Group 2: Technological Innovation - The company has established a comprehensive innovation system covering radioactive drugs, nuclide preparation, and nuclear medical equipment [1] - It focuses on addressing critical technology challenges and positions itself as a guardian of public health [1] Group 3: Sustainable Development - The company promotes green development to facilitate its transformation and upgrade [1] - It has innovated a circular economy development model for nuclear technology applications, achieving a balance between economic, environmental, and social benefits [1]

Core Viewpoint - China Tongru (01763) has been recognized for its ESG practices at the ESG China Innovation Annual Conference (2025), highlighting its commitment to health and sustainable development through nuclear technology [1] Group 1: ESG Recognition - The company received the China ESG Excellence Practice (2025) award from the China Enterprise Reform and Development Research Association [1] - It was also listed among the China ESG Listed Central Enterprises Pioneer 100 (2025) by the China Central Radio and Television [1] Group 2: Innovation and Development - The company has established a comprehensive innovation system covering radioactive drugs, nuclide preparation, and nuclear medical equipment [1] - It focuses on addressing critical technology challenges and positions itself as a guardian of public health [1] Group 3: Sustainable Development - The company promotes green development to facilitate its transformation and upgrade [1] - It has innovated a circular economy development model for nuclear technology applications, achieving synergy between economic, environmental, and social benefits [1]

Core Viewpoint - China Tongru (01763.HK) has been recognized for its ESG practices at the ESG China Innovation Conference (2025), highlighting its commitment to health and sustainable development through nuclear technology [1] Group 1: ESG Recognition - The company received the "China ESG Excellence Practice (2025)" award from the China Enterprise Reform and Development Research Association [1] - It was also listed among the "China ESG Listed Central Enterprises Pioneer 100 (2025)" by the China Central Radio and Television [1] Group 2: Innovation and Development - The company has established a comprehensive innovation system covering radioactive drugs, nuclide preparation, and nuclear medical equipment [1] - It emphasizes technological innovation to address critical technology challenges and positions itself as a guardian of public health [1] Group 3: Sustainable Development - The company promotes green development to facilitate its transformation and upgrade [1] - It aims to achieve a synergistic development of economic, environmental, and social benefits through innovative applications of nuclear technology and a circular economy model [1]

Core Viewpoint - China Dongfang (01763) has been recognized for its ESG practices at the ESG China Innovation Conference 2025, highlighting its commitment to health and sustainable development through nuclear technology [1] Group 1: ESG Recognition - The company received the China ESG Excellence Practice (2025) award from the China Enterprise Reform and Development Research Association [1] - It was also listed among the China ESG Listed Central Enterprises Pioneer 100 (2025) by the China Central Radio and Television [1] Group 2: Technological Innovation - The company is building a comprehensive innovation system covering radioactive drugs, nuclide preparation, and nuclear medical equipment [1] - It is focusing on addressing critical technology challenges and positioning itself as a guardian of public health [1] Group 3: Sustainable Development - The company promotes green development to facilitate its transformation and upgrade [1] - It aims to achieve a synergistic development of economic, environmental, and social benefits through innovative applications of nuclear technology and a circular economy model [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 自願性公告 中國同輻ESG實踐榮獲中國ESG卓越實踐(2025)和中國ESG上市公司央 企先鋒100(2025) 本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 本公司董事會欣然宣布，近日，中國企業改革與發展研究會與首鋼集團有限公司 共同主辦的ESG中國•創新年會(2025)在北京成功舉行，本公司《以核技術優勢打 造「健康中國」—— 核醫療中國同輻方案》ESG實踐榮獲中國企業改革與發展研究 會發布的中國ESG卓越實踐(2025)和中央廣播電視總台發布的中國ESG上市央企 先鋒100(2025)。 本公司以科技創新為引領，構建起覆蓋放射性藥物、核素製備、核醫療裝備的全 鏈條創新 ...

中国同辐(01763)公布，公司发行的中国同辐股份有限公司2024年面向专业投资者公开发行科技创新公 司债券(第一期)将于2025年10月27日(因2025年10月25日遇休息日，故顺延至其后的第1个交易日)开始支 付自2024年10月25日至2025年10月24日期间的利息。本期债券简称"24同辐K1"，发行总额5亿元，面利 率(计息年利率)为2.25%，每手本期债券面值为1,000元，派发利息为22.50元(含税)。 ...